<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB05102</drugbank-id>
  <name>Rupintrivir</name>
  <description>Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.</description>
  <cas-number>223537-30-2</cas-number>
  <unii>RGE5K1Q5QW</unii>
  <average-mass>598.6624</average-mass>
  <monoisotopic-mass>598.280277827</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3213</ref-id>
        <pubmed-id>17908951</pubmed-id>
        <citation>Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK: In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2007 Dec;51(12):4366-73. Epub 2007 Oct 1.</citation>
      </article>
      <article>
        <ref-id>A3214</ref-id>
        <pubmed-id>15673742</pubmed-id>
        <citation>Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patick AK: Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother. 2005 Feb;49(2):619-26.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in viral infection.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>The 3C protease (3CP) enzyme is central to rhinovirus replication. By binding to and inhibiting this enzyme, AG7088 prevents rhinovirus replication in cells of the respiratory tract and stops cold symptoms developing.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as 2-heteroaryl carboxamides. These are compounds containing a heteroaromatic ring that carries a carboxamide group.</description>
    <direct-parent>2-heteroaryl carboxamides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Carboxylic acid derivatives</subclass>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Enoate esters</alternative-parent>
    <alternative-parent>Fatty acid esters</alternative-parent>
    <alternative-parent>Fluorobenzenes</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Isoxazoles</alternative-parent>
    <alternative-parent>Ketones</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>N-acyl amines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Pyrrolidine-2-ones</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <substituent>2-heteroaryl carboxamide</substituent>
    <substituent>2-pyrrolidone</substituent>
    <substituent>Alpha,beta-unsaturated carboxylic ester</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Enoate ester</substituent>
    <substituent>Fatty acid ester</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Fluorobenzene</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Isoxazole</substituent>
    <substituent>Ketone</substituent>
    <substituent>Lactam</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-amine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrrolidone</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>rupintrivir</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Pyrrolidines</category>
      <mesh-id>D011759</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Rupintrivir.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.43</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.06e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>ethyl (2E,4S)-4-[(2R,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazol-3-yl)formamido]-4-oxoheptanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>ethyl (2E,4S)-4-[(2R,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazol-3-yl)formamido]-4-oxoheptanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>598.6624</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>598.280277827</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@H](C(C)C)NC(=O)C1=NOC(C)=C1)CC1=CC=C(F)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C31H39FN4O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C31H39FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-11,14,18,21-22,24,28H,5,12-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/b11-10+/t21-,22+,24+,28-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>CAYJBRBGZBCZKO-BHGBQCOSSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>156.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>157.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>62.48</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>0.035</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6440352</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175426944</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4944627</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>11243</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL20210</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0003372</id>
      <name>Genome polyprotein</name>
      <organism>HRV-14</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P03303" source="Swiss-Prot">
        <name>Genome polyprotein</name>
        <general-function>Structural molecule activity</general-function>
        <specific-function>Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host ICAM1 to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed "unlinkase". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location>Virion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.28</theoretical-pi>
        <molecular-weight>242989.38</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="12131">HRV-14</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K02121</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P03303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>POLG_HRV14</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.22.29</synonym>
          <synonym>P2A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017078|Genome polyprotein
MGAQVSTQKSGSHENQNILTNGSNQTFTVINYYKDAASTSSAGQSLSMDPSKFTEPVKDL
MLKGAPALNSPNVEACGYSDRVQQITLGNSTITTQEAANAVVCYAEWPEYLPDVDASDVN
KTSKPDTSVCRFYTLDSKTWTTGSKGWCWKLPDALKDMGVFGQNMFFHSLGRSGYTVHVQ
CNATKFHSGCLLVVVIPEHQLASHEGGNVSVKYTFTHPGERGIDLSSANEVGGPVKDVIY
NMNGTLLGNLLIFPHQFINLRTNNTATIVIPYINSVPIDSMTRHNNVSLMVIPIAPLTVP
TGATPSLPITVTIAPMCTEFSGIRSKSIVPQGLPTTTLPGSGQFLTTDDRQSPSALPNYE
PTPRIHIPGKVHNLLEIIQVDTLIPMNNTHTKDEVNSYLIPLNANRQNEQVFGTNLFIGD
GVFKTTLLGEIVQYYTHWSGSLRFSLMYTGPALSSAKLILAYTPPGARGPQDRREAMLGT
HVVWDIGLQSTIVMTIPWTSGVQFRYTDPDTYTSAGFLSCWYQTSLILPPETTGQVYLLS
FISACPDFKLRLMKDTQTISQTVALTEGLGDELEEVIVEKTKQTVASISSGPKHTQKVPI
LTANETGATMPVLPSDSIETRTTYMHFNGSETDVECFLGRAACVHVTEIQNKDATGIDNH
REAKLFNDWKINLSSLVQLRKKLELFTYVRFDSEYTILATASQPDSANYSSNLVVQAMYV
PPGAPNPKEWDDYTWQSASNPSVFFKVGDTSRFSVPYVGLASAYNCFYDGYSHDDAETQY
GITVLNHMGSMAFRIVNEHDEHKTLVKIRVYHRAKHVEAWIPRAPRALPYTSIGRTNYPK
NTEPVIKKRKGDIKSYGLGPRYGGIYTSNVKIMNYHLMTPEDHHNLIAPYPNRDLAIVST
GGHGAETIPHCNCTSGVYYSTYYRKYYPIICEKPTNIWIEGNPYYPSRFQAGVMKGVGPA
EPGDCGGILRCIHGPIGLLTAGGSGYVCFADIRQLECIAEEQGLSDYITGLGRAFGVGFT
DQISTKVTELQEVAKDFLTTKVLSKVVKMVSALVIICRNHDDLVTVTATLALLGCDGSPW
RFLKMYISKHFQVPYIERQANDGWFRKFNDACNAAKGLEWIANKISKLIEWIKNKVLPQA
KEKLEFCSKLKQLDILERQITTMHISNPTQEKREQLFNNVLWLEQMSQKFAPLYAVESKR
IRELKNKMVNYMQFKSKQRIEPVCVLIHGTPGSGKSLTTSIVGRAIAEHFNSAVYSLPPD
PKHFDGYQQQEVVIMDDLNQNPDGQDISMFCQMVSSVDFLPPMASLDNKGMLFTSNFVLA
STNSNTLSPPTILNPEALVRRFGFDLDICLHTTYTKNGKLNAGMSTKTCKDCHQPSNFKK
CCPLVCGKAISLVDRTTNIRYSVDQLVTAIISDFKSKMQITDSLETLFQGPVYKDLEIDV
CNTPPPECINDLLKSVDSEEIREYCKKKKWIIPEIPTNIERAMNQASMIINTILMFVSTL
GIVYVIYKLFAQTQGPYSGNPPHNKLKAPTLRPVVVQGPNTEFALSLLRKNIMTITTSKG
EFTGLGIHDRVCVIPTHAQPGDDVLVNGQKIRVKDKYKLVDPENINLELTVLTLDRNEKF
RDIRGFISEDLEGVDATLVVHSNNFTNTILEVGPVTMAGLINLSSTPTNRMIRYDYATKT
GQCGGVLCATGKIFGIHVGGNGRQGFSAQLKKQYFVEKQGQVIARHKVREFNINPVNTPT
KSKLHPSVFYDVFPGDKEPAVLSDNDPRLEVKLTESLFSKYKGNVNTEPTENMLVAVDHY
AGQLLSLDIPTSELTLKEALYGVDGLEPIDITTSAGFPYVSLGIKKRDILNKETQDTEKM
KFYLDKYGIDLPLVTYIKDELRSVDKVRLGKSRLIEASSLNDSVNMRMKLGNLYKAFHQN
PGVLTGSAVGCDPDVFWSVIPCLMDGHLMAFDYSNFDASLSPVWFVCLEKVLTKLGFAGS
SLIQSICNTHHIFRDEIYVVEGGMPSGCSGTSIFNSMINNIIIRTLILDAYKGIDLDKLK
ILAYGDDLIVSYPYELDPQVLATLGKNYGLTITPPDKSETFTKMTWENLTFLKRYFKPDQ
QFPFLVHPVMPMKDIHESIRWTKDPKNTQDHVRSLCMLAWHSGEKEYNEFIQKIRTTDIG
KCLILPEYSVLRRRWLDLF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017079|Genome polyprotein
ATGGGCGCTCAGGTTTCTACACAGAAAAGTGGATCTCACGAAAATCAAAACATTTTGACC
AATGGATCAAATCAGACTTTCACAGTTATAAATTACTATAAGGATGCAGCAAGTACATCA
TCAGCTGGTCAATCACTGTCAATGGACCCATCTAAGTTTACAGAACCAGTTAAAGATCTC
ATGCTTAAGGGTGCACCAGCATTGAATTCACCCAATGTTGAGGCCTGTGGTTATAGTGAT
AGAGTACAACAAATCACACTCGGGAATTCAACAATAACAACACAAGAAGCAGCCAACGCT
GTTGTGTGTTATGCTGAATGGCCAGAGTACCTTCCAGATGTGGACGCTAGTGATGTCAAT
AAAACTTCAAAACCAGACACTTCTGTCTGTAGGTTTTACACATTGGATAGTAAGACATGG
ACAACAGGTTCTAAAGGCTGGTGCTGGAAATTACCAGATGCACTCAAGGATATGGGTGTG
TTCGGGCAAAACATGTTTTTCCACTCACTAGGAAGATCAGGTTACACAGTACACGTTCAG
TGCAATGCCACAAAATTCCATAGCGGTTGTCTACTTGTAGTTGTAATACCAGAACACCAA
CTGGCTTCACATGAGGGTGGCAATGTTTCAGTTAAATACACATTCACGCATCCAGGTGAA
CGTGGTATAGATTTATCATCTGCAAATGAAGTGGGAGGGCCTGTCAAGGATGTCATATAC
AATATGAATGGTACTTTATTAGGAAATCTGCTCATTTTCCCTCACCAGTTCATTAATCTA
AGAACCAATAATACAGCCACAATAGTGATACCATACATAAACTCAGTACCCATTGATTCA
ATGACACGTCACAACAATGTCTCACTGATGGTCATCCCTATTGCCCCTCTTACAGTACCA
ACTGGAGCAACTCCCTCACTCCCTATAACAGTCACAATAGCACCTATGTGCACTGAGTTC
TCTGGGATAAGGTCCAAGTCAATTGTGCCACAAGGTTTGCCAACTACAACTTTGCCGGGG
TCAGGACAATTCTTGACCACAGATGACAGGCAATCCCCCAGTGCACTGCCAAATTATGAG
CCAACTCCAAGAATACACATACTAGGGAAAGTTCATAACTTGCTAGAAATTATACAGGTA
GATACACTCATTCCTATGAACAACACGCATACAAAAGATGAGGTTAACAGTTACCTCATA
CCACTAAATGCAAACAGGCAAAATGAGCAGGTTTTTGGGACAAACCTGTTTATTGGTGAT
GGGGTCTTCAAAACTACTCTTCTGGGTGAAATTGTTCAGTACTATACACATTGGTCTGGA
TCACTTAGATTCTCTTCGATGTATACTGGTCCTGCCTTGTCCAGTGCTAAACTCACTCTA
GCATACACCCCGCCTGGTGCTCGTGGTCCACAGGACAGGAGAGAAGCAATGCTAGGTACT
CATGTTGTCTGGGATATTGGTCTGCAATCCACCATAGTAATGACAATACCATGGACATCA
GGGGTGCAGTTTAGATATACTGATCCAGATACATACACCAGTGCTGGCTTTCTATCATGT
TGGTATCAAACTTCTCTTATACTTCCCCCAGAAACGACCGGCCAGGTCTACTTATTATCA
TTCATAAGTGCATGTCCAGATTTTAAGCTTAGGCTGATGAAAGATACTCAAACTATCTCA
CAGACTGTTGCACTCACTGAAGGCTTAGGTGATGAATTAGAAGAAGTCATCGTTGAGAAA
ACGAAACAGACGGTGGCCTCAATCTCATCTGGTCCAAAACACACACAAAAAGTCCCCATA
CTAACTGCAAACGAAACAGGGGCCACAATGCCTGTTCTTCCATCAGACAGCATAGAAACC
AGAACTACCTACATGCACTTTAATGGTTCAGAAACTGATGTAGAATGCTTTTTGGGTCGT
GCAGCTTGTGTGCATGTAACTGAAATACAAAACAAAGATGCTACTGGAATAGATAATCAC
AGAGAAGCAAAATTGTTCAATGATTGGAAAATCAACCTGTCCAGCCTTGTCCAACTTAGA
AAGAAACTGGAACTCTTCACTTATGTTAGGTTTGATTCTGAGTATACCATACTGGCCACT
GCATCTCAACCTGATTCAGCAAACTATTCAAGCAATTTGGTGGTCCAAGCCATGTATGTT
CCACATGGTGCCCCGAAATCCAAAAGAGTGGGCGATTACACATGGCAAAGTGCTTCAAAC
CCCAGTGTATTCTTCAAGGTGGGGGATACATCAAGGTTTAGTGTGCCTTATGTAGGATTG
GCATCAGCATATAATTGTTTTTATGATGGTTACTCACATGATGATGCAGAAACTCAGTAT
GGCATAACTGTTCTAAACCATATGGGTAGTATGGCATTCAGAATAGTAAATGAACATGAT
GAACACAAAACTCTTGTCAAGATCAGAGTTTATCACAGGGCAAAGCTCGTTGAAGCATGG
ATTCCAAGAGCACCCAGAGCACTACCCTACACATCAATAGGGCGCACAAATTATCCTAAG
AATACAGAACCAGTAATTAAGAAGAGGAAAGGTGACATTAAATCCTATGGTTTAGGACCT
AGGTACGGTGGGATTTATACATCAAATGTTAAAATAATGAATTACCACTTGATGACACCA
GAAGACCACCATAATCTGATAGCACCCTATCCAAATAGAGATTTAGCAATAGTCTCAACA
GGAGGACATGGTGCAGAAACAATACCACACTGTAACCGTACATCAGGTGTTTACTATTCC
ACATATTACAGAAAGTATTACCCCATAATTTGCGAAAAGCCCACCAACATCTGGATTGAA
GGAAGCCCTTATTACCCAAGTAGATTTCAAGCAGGAGTGATGAAAGGGGTTGGGCCGGCA
GAGCTAGGAGACTGCGGTGGGATTTTGAGATGCATACATGGTCCCATTGGATTGTTAACA
GCTGAAGGTAGTGGATATGTTTGTTTTGCTGACATACGACAGTTGGAGTGTATCGCAGAG
GAACAGGGGCTGAGTGATTACATCACAGGTTTGGGTAGAGCTTTTGGTGTCGGGTTCACT
GACCAAATCTCAACAAAAGTCACAGAACTACAAGAAGTGGCGAAAGATTTCCTCACCACA
AAAGTTTTGTCCAAAGTGGTCAAAATGGTTTCAGCTTTAGTGATCATTTGCAGAAATCAT
GATGACTTGGTCACTGTTACGGCCACTCTAGCACTACTTGGATGTGATGGATCTCCTTGG
AGATTTCTGAAGATGTACATTTCCAAACACTTTCAGGTGCCTTACATTGAAAGACAAGCA
AATGATGGATGGTTCAGAAAGTTTAATGATGCATGTAATGCTGCAAAGGGATTGGAATGG
ATTGCTAATAAGATTTCCAAACTGATTGAATGGATAAAAAACAAAGTACTTCCCCAAGCC
AAAGAAAAACTAGAATTTTGTAGTAAACTCAAACAACTTGATATACTAGAGAGACAAATA
ACCACCATGCATATCTCGAATCCAACACAGGAAAAACGAGAGCAGTTGTTCAATAACGTA
TTGTGGTTGGAACAAATGTCGCAAAAGTTTGCCCCATTTTATGCCGTTGAATCAAAAAGA
ATCAGGGAACTCAAGAACAAAATGGTAAATTATATGCAATTTAAAAGTAAACAAAGAACT
GAACCAGTGTGTGTATTAATCCATGGTACACCCGGTTCTGGTAAATCATTAACAACATCC
ATTGTGGGACGTGCAATTGCAGAACACTTCAATTCAGCAGTATATTCACTTCCACCAGAT
CCCAAGCACTTTGATGGTTATCAGCAACAGGAAGTTGTGATTATGGATGATCTGAACCAA
AATCCAGATGGACAGGATATAAGCATGTTTTGTCAAATGGTTTCTTCAGTGGATTTCTTG
CCTCCAATGGCTAGTTTAGATAACAAGGGCATGTTATTCACCAGTAATTTTGTTCTAGCC
TCCACAAATTCTAACACACTAAGCCCCCCAACAATCTTGAATCCTGAAGCTTTAGTCAGG
AGATTTGGTTTTGACCTAGATATATGTTTGCATACTACCTACACAAAGAATGGAAAACTC
AATGCAGGCATGTCAACCAAGACATGCAAAGATTGCCATCAACCATCTAATTTCAAGAAA
TGTTGCCCCCTAGTCTGTGGAAAAGCTATTAGCTTGGTAGACAGAACTACCAACGTTAGG
TATAGTGTGGATCAACTGGTCACGGCTATTATAAGTGATTTCAAGAGCAAAATGCAAATT
ACAGATTCCCTAGAAACACTGTTTCAAGGACCAGTGTATAAAGATTTAGAGATTGATGTT
TGCAACACACCACCTTCAGAATGTATCAACGATTTACTGAAATCTGTAGATTCAGAAGAG
ATTAGGGAATATTGTAAGAAGAAGAAATGGATTATACCTGAAATTCCTACCAACATAGAA
AGGGCTATGAATCAAGCCAGCATGATTATTAATACTATTCTGATGTTTGTCAGTACATTA
GGTATTGTTTATGTCATTTATAAATTGTTTGCTCAAACTCAAGGACCATATTCTGGTAAC
CCGCCTCACAATAAACTAAAAGCCCCAACTTTACGCCCAGTTGTTGTGCAAGGACCAAAC
ACAGAATTTGCACTATCCCTGTTAAGGAAAAACATAATGACTATAACAACCTCAAAGGGA
GAGTTCACAGGGTTAGGCATACATGATCGTGTCTGTGTGATACCCACACACGCACAGCCT
GGTGATGATGTACTAGTGAATGGTCAGAAAATTAGAGTTAAGGATAAGTACAAATTAGTA
GATCCAGAGAACATTAATCTAGAGCTTACAGTGTTGACTTTAGATAGAAATGAAAAATTC
AGAGATATCAGGGGATTTATATCAGAAGATCTAGAAGGTGTGGATGCCACTTTGGTAGTA
CATTCAAATAACTTTACCAACACTATCTTAGAAGTTGGCCCTGTAACAATGGCAGGACTT
ATTAATTTGAGTAGCACCCCCACTAACAGAATGATTCGTTATGATTATGCAACAAAAACT
GGGCAGTGTGGAGGTGTGCTGTGTGCTACTGGTAAGATCTTTGGTATTCATGTTGGCGGT
AATGGAAGACAAGGATTTTCAGCTCAACTTAAAAAACAATATTTTGTAGAGAAACAAGGC
CAAGTAATAGCTAGACATAAGGTTAGGGAGTTTAACATAAATCCAGTCAACACGGCAACT
AAGTCAAAATTACATCCCAGTGTATTTTATGATGTTTTTCCAGGTGACAAGGAACCTGCT
GTATTGAGTGACAATGATCCCAGACTGGAAGTTAAATTGACTGAATCATTATTCTCTAAG
TACAAGGGGAATGTAAATACGGAACCCACTGAAAATATGCTTGTGGCTGTAGACCATTAT
GCAGGGCAACTATTATCACTAGATATCCCCACTTCTGAACTTACACTAAAAGAAGCATTA
TATGGAGTAGATGGACTAGAACCTATAGATATTACAACCAGTGCAGGATTTCCCTATGTG
AGTCTTGGGATCAAAAAGAGAGACATTCTGAATAAAGAGACCCAGGACACAGAAAAGATG
AAGTTTTATCTAGACAAGTATGGCATTGACTTGCCTCTAGTTACATATATTAAGGATGAA
TTAAGAAGTGTTGACAAAGTCCGATTAGGGAAAAGTAGATTAATTGAAGCCTCCAGTTTG
AATGATTCTGTTAACATGAGAATGAAACTAGGCAACCTTTACAAAGCATTCCATCAAAAT
CCCGGTGTTCTGACTGGATCAGCAGTGGGTTGTGATCCTGATGTGTTTTGGTCTGTCATC
CCTTGCTTAATGGATGGGCACCTGATGGCATTTGATTACTCTAATTTTGATGCCTCTTTG
TCACCAGTTTGGTTTGTCTGTCTAGAGAAGGTTTTGACCAAGTTAGGCTTTGCAGGCTCT
TCATTAATTCAATCAATTTGTAATACCCATCATATCTTTAGGGATGAAATATATGTGGTT
GAAGGTGGCATGCCCTCAGGGTGTTCAGGAACCAGCATATTCAATTCCATGATCAACAAC
ATAATCATTAGGACTTTGATATTAGATGCATATAAAGGAATAGATTTAGACAAACTTAAA
ATCTTAGCTTACGGTGATGATTTGATTGTTTCTTATCCTTATGAACTGGATCCACAAGTG
TTGGCAACTCTTGGTAAAAATTATGGACTAACCATCACACCCCCAGACAAATCTGAAACT
TTTACAAAAATGACATGGGAAAACTTGACATTTTTAAAGAGATACTTCAAGCCTGATCAA
CAATTTCCCTTTTTGGTTCACCCAGTTATGCCCATGAAAGATATACATGAGTCAATCAGA
TGGACAAAGGATCCTAAAAACACACAGGATCACGTCCGATCATTATGCATGTTAGCATGG
CACTCAGGAGAAAAAGAGTACAATGAATTCATTCAGAAGATCAGAACTACTGACATTGGA
AAATGTCTAATTCTCCCAGAATACAGCGTACTTAGGAGGCGCTGGTTGGACCTCTTTTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00680</identifier>
            <name>RdRP_1</name>
          </pfam>
          <pfam>
            <identifier>PF08727</identifier>
            <name>P3A</name>
          </pfam>
          <pfam>
            <identifier>PF00548</identifier>
            <name>Peptidase_C3</name>
          </pfam>
          <pfam>
            <identifier>PF02226</identifier>
            <name>Pico_P1A</name>
          </pfam>
          <pfam>
            <identifier>PF00947</identifier>
            <name>Pico_P2A</name>
          </pfam>
          <pfam>
            <identifier>PF01552</identifier>
            <name>Pico_P2B</name>
          </pfam>
          <pfam>
            <identifier>PF00073</identifier>
            <name>Rhv</name>
          </pfam>
          <pfam>
            <identifier>PF00910</identifier>
            <name>RNA_helicase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell cytoplasmic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral to membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>T=pseudo3 icosahedral viral capsid</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA helicase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-directed RNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural molecule activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocytosis involved in viral entry into host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>induction by virus of host autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lysis of host organelle involved in viral entry into host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pore formation by virus in membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pore-mediated entry of viral genome into host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive stranded viral RNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>RNA-protein covalent cross-linking</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host mRNA export from nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host RIG-I activity by RIG-I proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host translation initiation factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral RNA genome replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>virion attachment to host cell</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>